The collaboration combines Profluent’s generative AI platform with IDT’s enzyme engineering and genomics expertise to accelerate development of next-generation enzymes.
Integrated DNA Technologies (IDT), a Danaher company, has entered a strategic collaboration with Profluent Bio to design and optimize next-generation enzymes using artificial intelligence (AI)-driven protein design.
The partnership combines Profluent’s generative AI platform with IDT’s enzyme engineering and genomics capabilities to develop novel enzyme variants for applications including epigenetics and cancer research. The collaboration also supports IDT’s recently established innovation center in the Bay Area as the company expands its oncology research capabilities.
“At IDT, we’ve built a strong enzyme engineering capability—innovating proprietary enzymes that have powered countless scientific breakthroughs,” says IDT president Ajay Gannerkote in a release. “This collaboration with Profluent Bio represents a bold step forward in our strategic roadmap. By integrating Profluent’s AI-driven protein design with IDT’s enzymology and genomics expertise, we will unearth new possibilities across a broad range of critical applications, from epigenetics to cancer research and beyond.”
AI Models Trained on Multibillion-Sequence Dataset
Profluent’s foundational models, including ProGen3, are trained on the Profluent Protein Atlas, a curated multibillion-sequence dataset designed to enable biological understanding and alignment with experimental data. The company’s AI technology has produced innovations including OpenCRISPR-1, which the company describes as an AI-generated gene editor.
IDT will use its enzyme development infrastructure, genomics expertise, and global manufacturing capabilities to test, validate, and scale Profluent-designed sequences for its product development pipeline. As a Danaher operating company, IDT is positioned to accelerate translation of AI-driven designs into production-ready enzymes for next-generation sequencing, synthetic biology, and gene editing applications.
“Pairing Profluent’s AI with IDT’s world-class enzymology and manufacturing expertise is a powerful way to bring new capabilities to researchers and the industry,” says Ali Madani, PhD, founder and CEO of Profluent Bio, in a release. “This partnership reflects our belief that AI-designed proteins can unlock step-changes in enzyme efficiency, precision, and manufacturability, without being constrained by what evolution has already tried.”
Focus on Laboratory Applications
The collaboration aims to streamline development from computational designs to laboratory-ready biological tools. IDT’s enzyme engineering capabilities have supported various scientific applications, while the partnership with Profluent is expected to enhance customization options for laboratory customers.
Danaher has been investing in AI for molecular design across its operating companies, positioning IDT to leverage these enterprise-wide capabilities in enzyme development.
Profluent Bio, founded in 2022 and headquartered in Emeryville, California, focuses on AI-driven protein design for applications in medicine and agriculture. The company is backed by investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures and Convergent Ventures.
IDT products are labeled for research use only and are not intended for diagnostic procedures unless otherwise specified in writing.
ID 32581342 | Artificial Intelligence Laboratory © Agsandrew | Dreamstime.com
